Comparative Pharmacology
Head-to-head clinical analysis: VOLTAREN XR versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VOLTAREN XR versus ZIPSOR.
VOLTAREN-XR vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
100 mg orally once daily, extended-release formulation. Maximum 150 mg/day (divided as 75 mg twice daily or 100 mg once daily).
50 mg orally three times daily
None Documented
None Documented
The terminal elimination half-life is approximately 2 hours. The extended-release formulation (XR) does not alter the half-life; it maintains prolonged therapeutic plasma concentrations with twice-daily dosing.
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Approximately 65% of a dose is excreted renally as unchanged drug and metabolites (primarily as glucuronide conjugates); about 35% is eliminated via bile in feces.
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category C
Category C
NSAID
NSAID